51
|
Contreras C, Nogueiras R, Diéguez C, Rahmouni K, López M. Traveling from the hypothalamus to the adipose tissue: The thermogenic pathway. Redox Biol 2017; 12:854-863. [PMID: 28448947 PMCID: PMC5406580 DOI: 10.1016/j.redox.2017.04.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 04/08/2017] [Accepted: 04/11/2017] [Indexed: 01/13/2023] Open
Abstract
Brown adipose tissue (BAT) is a specialized tissue critical for non-shivering thermogenesis producing heat through mitochondrial uncoupling; whereas white adipose tissue (WAT) is responsible of energy storage in the form of triglycerides. Another type of fat has been described, the beige adipose tissue; this tissue emerges in existing WAT depots but with thermogenic ability, a phenomenon known as browning. Several peripheral signals relaying information about energy status act in the brain, particularly the hypothalamus, to regulate thermogenesis in BAT and browning of WAT. Different hypothalamic areas have the capacity to regulate the thermogenic process in brown and beige adipocytes through the sympathetic nervous system (SNS). This review discusses important concepts and discoveries about the central control of thermogenesis as a trip that starts in the hypothalamus, and taking the sympathetic roads to reach brown and beige fat to modulate thermogenic functions.
Collapse
Affiliation(s)
- Cristina Contreras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Kamal Rahmouni
- Department of Pharmacology, University of Iowa, Iowa City, Iowa 52242, USA; Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa 52242, USA
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
| |
Collapse
|
52
|
Novelle MG, Vázquez MJ, Peinado JR, Martinello KD, López M, Luckman SM, Tena-Sempere M, Malagón MM, Nogueiras R, Diéguez C. Sequential Exposure to Obesogenic Factors in Females Rats: From Physiological Changes to Lipid Metabolism in Liver and Mesenteric Adipose Tissue. Sci Rep 2017; 7:46194. [PMID: 28387334 PMCID: PMC5384043 DOI: 10.1038/srep46194] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 03/10/2017] [Indexed: 12/16/2022] Open
Abstract
During their lifetime, females are subjected to different nutritional and hormonal factors that could increase the risk of obesity and associated comorbidities. From early postnatal periods until the postmenopausal phase, exposure to over nutrition, high-energy diet and oestrogen deficiency, are considered as significant obesity risk factors in women. In this study, we assessed how key transitional life events and exposure to different nutrition influence energy homeostasis in a rat model. Specifically, we assessed the sequential exposure to postnatal over nutrition, high-fat diet (HFD) after weaning, followed later by ovariectomy (OVX; as a model of menopause). Each obesity risk factor increased significantly body weight (BW) and adiposity, with additive effects after sequential exposure. Increased energy intake in both HFD and/or OVX groups, and decreased locomotor activity and energy expenditure after OVX can explain these metabolic changes. Our study also documents decreased lipogenic pathway in mesenteric adipose tissue after HFD and/or OVX, independent of previous postnatal programming, yet only HFD evoked this effect in liver. In addition, we report an increase in the expression of the hepatic PEPCK depending on previous metabolic status. Overall, our results identify the impact of different risk factors, which will help in understanding the development of obesity in females.
Collapse
Affiliation(s)
- Marta G Novelle
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Santiago de Compostela, Spain.,Faculty of Biology, Medicine and Health, University of Manchester, AV Hill Building, Manchester, UK
| | - María J Vázquez
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,Department of Medical Sciences, Faculty of Medicine, Ciudad Real, Spain
| | - Juan R Peinado
- Department of Medical Sciences, Faculty of Medicine, Ciudad Real, Spain
| | - Kátia D Martinello
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Santiago de Compostela, Spain
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Santiago de Compostela, Spain
| | - Simon M Luckman
- Faculty of Biology, Medicine and Health, University of Manchester, AV Hill Building, Manchester, UK
| | - Manuel Tena-Sempere
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,Department of Medical Sciences, Faculty of Medicine, Ciudad Real, Spain
| | - María M Malagón
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/University of Córdoba/Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Córdoba, Spain.,Department of Medical Sciences, Faculty of Medicine, Ciudad Real, Spain
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Santiago de Compostela, Spain
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Santiago de Compostela, Spain
| |
Collapse
|
53
|
Tudurí E, Imbernon M, Hernández-Bautista RJ, Tojo M, Fernø J, Diéguez C, Nogueiras R. GPR55: a new promising target for metabolism? J Mol Endocrinol 2017; 58:R191-R202. [PMID: 28196832 DOI: 10.1530/jme-16-0253] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 02/14/2017] [Indexed: 01/05/2023]
Abstract
GPR55 is a G-protein-coupled receptor (GPCR) that has been identified as a new cannabinoid receptor. Given the wide localization of GPR55 in brain and peripheral tissues, this receptor has emerged as a regulator of multiple biological actions. Lysophosphatidylinositol (LPI) is generally accepted as the endogenous ligand of GPR55. In this review, we will focus on the role of GPR55 in energy balance and glucose metabolism. We will summarize its actions on feeding, nutrient partitioning, gastrointestinal motility and insulin secretion in preclinical models and the scarce data available in humans. The potential of GPR55 to become a new pharmaceutical target to treat obesity and type 2 diabetes, as well as the foreseeing difficulties are also discussed.
Collapse
Affiliation(s)
- Eva Tudurí
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - Monica Imbernon
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of PhysiologyCIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Rene Javier Hernández-Bautista
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of PhysiologyCIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Marta Tojo
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of PhysiologyCIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Johan Fernø
- Department of Clinical ScienceKG Jebsen Center for Diabetes Research, University of Bergen, Bergen, Norway
| | - Carlos Diéguez
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of PhysiologyCIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Rubén Nogueiras
- Instituto de Investigaciones Sanitarias (IDIS)CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of PhysiologyCIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
54
|
Martínez-Sánchez N, Moreno-Navarrete JM, Contreras C, Rial-Pensado E, Fernø J, Nogueiras R, Diéguez C, Fernández-Real JM, López M. Thyroid hormones induce browning of white fat. J Endocrinol 2017; 232:351-362. [PMID: 27913573 PMCID: PMC5292977 DOI: 10.1530/joe-16-0425] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Accepted: 12/02/2016] [Indexed: 12/17/2022]
Abstract
The canonical view about the effect of thyroid hormones (THs) on thermogenesis assumes that the hypothalamus acts merely as a modulator of the sympathetic outflow on brown adipose tissue (BAT). Recent data have challenged that vision by demonstrating that THs act on the ventromedial nucleus of the hypothalamus (VMH) to inhibit AMP-activated protein kinase (AMPK), which regulates the thermogenic program in BAT, leading to increased thermogenesis and weight loss. Current data have shown that in addition to activation of brown fat, the browning of white adipose tissue (WAT) might also be an important thermogenic mechanism. However, the possible central effects of THs on the browning of white fat remain unclear. Here, we show that 3,3',5,5' tetraiodothyroxyne (T4)-induced hyperthyroidism promotes a marked browning of WAT. Of note, central or VMH-specific administration of 3,3',5-triiodothyronine (T3) recapitulates that effect. The specific genetic activation of hypothalamic AMPK in the VMH reversed the central effect of T3 on browning. Finally, we also showed that the expression of browning genes in human WAT correlates with serum T4 Overall, these data indicate that THs induce browning of WAT and that this mechanism is mediated via the central effects of THs on energy balance.
Collapse
Affiliation(s)
- Noelia Martínez-Sánchez
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - José M Moreno-Navarrete
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of DiabetesEndocrinology and Nutrition, Hospital de Girona 'Dr Josep Trueta', Institut D'investigació Biomèdica de Girona (IdIBGi) and University of Girona, Girona, Spain
| | - Cristina Contreras
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - Eva Rial-Pensado
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - Johan Fernø
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- Department of Clinical ScienceKG Jebsen Center for Diabetes Research, University of Bergen, Bergen, Norway
| | - Rubén Nogueiras
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - Carlos Diéguez
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| | - José-Manuel Fernández-Real
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
- Department of DiabetesEndocrinology and Nutrition, Hospital de Girona 'Dr Josep Trueta', Institut D'investigació Biomèdica de Girona (IdIBGi) and University of Girona, Girona, Spain
| | - Miguel López
- Department of PhysiologyCIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de Compostela, Spain
| |
Collapse
|
55
|
Contreras C, González-García I, Seoane-Collazo P, Martínez-Sánchez N, Liñares-Pose L, Rial-Pensado E, Fernø J, Tena-Sempere M, Casals N, Diéguez C, Nogueiras R, López M. Reduction of Hypothalamic Endoplasmic Reticulum Stress Activates Browning of White Fat and Ameliorates Obesity. Diabetes 2017; 66:87-99. [PMID: 27634226 DOI: 10.2337/db15-1547] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Accepted: 09/09/2016] [Indexed: 11/13/2022]
Abstract
The chaperone GRP78/BiP (glucose-regulated protein 78 kDa/binding immunoglobulin protein) modulates protein folding in reply to cellular insults that lead to endoplasmic reticulum (ER) stress. This study investigated the role of hypothalamic GRP78 on energy balance, with particular interest in thermogenesis and browning of white adipose tissue (WAT). For this purpose, we used diet-induced obese rats and rats administered thapsigargin, and by combining metabolic, histologic, physiologic, pharmacologic, thermographic, and molecular techniques, we studied the effect of genetic manipulation of hypothalamic GRP78. Our data showed that rats fed a high-fat diet or that were centrally administered thapsigargin displayed hypothalamic ER stress, whereas genetic overexpression of GRP78 specifically in the ventromedial nucleus of the hypothalamus was sufficient to alleviate ER stress and to revert the obese and metabolic phenotype. Those effects were independent of feeding and leptin but were related to increased thermogenic activation of brown adipose tissue and induction of browning in WAT and could be reversed by antagonism of β3 adrenergic receptors. This evidence indicates that modulation of hypothalamic GRP78 activity may be a potential strategy against obesity and associated comorbidities.
Collapse
Affiliation(s)
- Cristina Contreras
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Ismael González-García
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Patricia Seoane-Collazo
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Noelia Martínez-Sánchez
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Laura Liñares-Pose
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Eva Rial-Pensado
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Johan Fernø
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- Department of Clinical Science, K.G. Jebsen Center for Diabetes Research, University of Bergen, Bergen, Norway
| | - Manuel Tena-Sempere
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
- Department of Cell Biology, Physiology and Immunology, University of Córdoba, and Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Reina Sofía, Córdoba, Spain
- Finland Distinguished Professor Program, Department of Physiology, University of Turku, Turku, Finland
| | - Núria Casals
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
- Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
| | - Carlos Diéguez
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Rubén Nogueiras
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Miguel López
- Department of Physiology, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| |
Collapse
|
56
|
González-García I, Fernø J, Diéguez C, Nogueiras R, López M. Hypothalamic Lipids: Key Regulators of Whole Body Energy Balance. Neuroendocrinology 2017; 104:398-411. [PMID: 27728904 DOI: 10.1159/000448432] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 07/17/2016] [Indexed: 11/19/2022]
Abstract
Hypothalamic lipid metabolism plays a major role in the physiological regulation of energy balance. Modulation of several enzymatic activities that control lipid biosynthesis, such as fatty acid synthase and AMP-activated protein kinase, impacts both feeding and energy expenditure. However, lipids can also cause pathological alterations in the hypothalamus. Lipotoxicity is promoted by excess lipids in tissues not suitable for their storage. A large amount of evidence has demonstrated that lipotoxicity is a pathophysiological mechanism leading to metabolic diseases such as insulin resistance, cardiomyopathy, atherosclerosis, and steatohepatitis. Current data have reported that, similar to what is observed in peripheral tissues, complex lipids such as ceramides and sphingolipids act as lipotoxic species at the hypothalamic level to impact metabolism. Here, we will review what is currently known about hypothalamic lipid metabolism and the modulation of energy homeostasis.
Collapse
Affiliation(s)
- Ismael González-García
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | | | | | | | | |
Collapse
|
57
|
Contreras C, Nogueiras R, Diéguez C, Medina-Gómez G, López M. Hypothalamus and thermogenesis: Heating the BAT, browning the WAT. Mol Cell Endocrinol 2016; 438:107-115. [PMID: 27498420 DOI: 10.1016/j.mce.2016.08.002] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 07/30/2016] [Accepted: 08/01/2016] [Indexed: 12/20/2022]
Abstract
Brown adipose tissue (BAT) has been also considered as the main thermogenic organ responsible of maintenance body temperature through heat production. However, a new type of thermogenic fat has been characterized during the last years, the beige or brite fat, that is developed from white adipose tissue (WAT) in response to different stimuli by a process known as browning. The activities of brown and beige adipocytes ameliorate metabolic disease, including obesity in mice and correlate with leanness in humans. Many genes and pathways that regulate brown and beige adipocyte biology have now been identified, providing a variety of promising therapeutic targets for metabolic disease. The hypothalamus is the main central place orchestrating the outflow signals that drive the sympathetic nerve activity to BAT and WAT, controlling heat production and energy homeostasis. Recent data have revealed new hypothalamic molecular mechanisms, such as hypothalamic AMP-activated protein kinase (AMPK), that control both thermogenesis and browning. This review provides an overview of the factors influencing BAT and WAT thermogenesis, with special focus on the integration of peripheral information on hypothalamic circuits controlling thermoregulation.
Collapse
Affiliation(s)
- Cristina Contreras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain.
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Gema Medina-Gómez
- Área de Bioquímica y Biología Molecular, Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, 28922, Alcorcón, Madrid, Spain
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain.
| |
Collapse
|
58
|
Decara J, Arrabal S, Beiroa D, Rivera P, Vargas A, Serrano A, Pavón FJ, Ballesteros J, Dieguez C, Nogueiras R, Rodríguez de Fonseca F, Suárez J. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators. Biofactors 2016; 42:600-611. [PMID: 27213962 DOI: 10.1002/biof.1295] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 04/18/2016] [Indexed: 12/25/2022]
Abstract
To investigate the role of glucagon-like-peptide-1 receptor (GLP-1R) in peripheral lipid metabolism. Both lean and high-fat diet (HFD)-induced obesity (DIO) rats were used to compare the peripheral effects of the subcutaneous and repeated administration of the GLP-1R agonist liraglutide on the expression of key regulators involved in lipid metabolism, β-oxidation and thermogenesis in liver, abdominal muscle, and epididymal white adipose tissue (eWAT). We observed that liraglutide reduced caloric intake, body weight, and plasma levels of triglycerides and VLDL in a diet-independent manner. However, changes in liver fat content and the expression of lipid metabolism regulators were produced in a diet and tissue-dependent manner. In lean rats, liraglutide increased the gene/protein expression of elements involved in lipogenesis (ChREBP, Acaca/ACC, Fasn/FAS, Scd1/SCD1, PPARα/γ), β-oxidation (CPT1b), and thermogenesis (Cox4i1, Ucp1/UCP1) in eWAT and muscle, which suggest an increase in fatty-acid flux and utilization to activate energy expenditure. Regarding DIO rats, the specific reduction of liver lipid content by liraglutide was associated with a decreased expression of main elements involved in lipogenesis (phospho-ACC), peroxisomal β-oxidation (ACOX1), and lipid flux/storage (Pparγ/PPARγ) in liver, which suggest a recovery of lipid homeostasis. Interestingly, the muscle of DIO rats treated with liraglutide showed a decreased expression of PPARγ and the thermogenic factor UCP1. These results help us to better understand the peripheral mechanisms regulating lipid metabolism that underlay the effectiveness of GLP-1 analogues for the treatment of diabetes and obesity. © 2016 BioFactors, 42(6):600-611, 2016.
Collapse
Affiliation(s)
- Juan Decara
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Sergio Arrabal
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Daniel Beiroa
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
- Department of Physiology, School of Medicine-CIMUS, University of Santiago De Compostela-Instituto De Investigación Sanitaria, S. Francisco S/N, 15782 Santiago De Compostela, Spain
| | - Patricia Rivera
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Antonio Vargas
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Antonia Serrano
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Francisco Javier Pavón
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Joan Ballesteros
- Parque Científico Madrid (PCM), VIVIA Biotech SL, 1 Calle Santiago Grisolia, Suite 205, Tres Cantos, 28760, Spain
| | - Carlos Dieguez
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
- Department of Physiology, School of Medicine-CIMUS, University of Santiago De Compostela-Instituto De Investigación Sanitaria, S. Francisco S/N, 15782 Santiago De Compostela, Spain
| | - Rubén Nogueiras
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
- Department of Physiology, School of Medicine-CIMUS, University of Santiago De Compostela-Instituto De Investigación Sanitaria, S. Francisco S/N, 15782 Santiago De Compostela, Spain
| | - Fernando Rodríguez de Fonseca
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| | - Juan Suárez
- UGC Salud Mental, Instituto De Investigación Biomédica De Málaga (IBIMA), Universidad De Málaga-Hospital Universitario Regional De Málaga, Avda. Carlos Haya 82, Pabellón De Gobierno, Málaga, Spain
- CIBER OBN, Instituto De Salud Carlos III, Madrid, Spain
| |
Collapse
|
59
|
Tudurí E, Beiroa D, Stegbauer J, Fernø J, López M, Diéguez C, Nogueiras R. Acute stimulation of brain mu opioid receptors inhibits glucose-stimulated insulin secretion via sympathetic innervation. Neuropharmacology 2016; 110:322-332. [DOI: 10.1016/j.neuropharm.2016.08.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 07/10/2016] [Accepted: 08/05/2016] [Indexed: 01/19/2023]
|
60
|
Pardo R, Blasco N, Vilà M, Beiroa D, Nogueiras R, Cañas X, Simó R, Sanchis D, Villena JA. EndoG Knockout Mice Show Increased Brown Adipocyte Recruitment in White Adipose Tissue and Improved Glucose Homeostasis. Endocrinology 2016; 157:3873-3887. [PMID: 27547848 DOI: 10.1210/en.2015-1334] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Brown adipose tissue (BAT) plays a central role in the regulation of whole-body energy and glucose homeostasis owing to its elevated capacity for lipid and glucose oxidation. The BAT thermogenic function, which is essential for the defense of body temperature against exposure to low environmental temperatures, relies on the expression in the inner membrane of brown adipocyte's mitochondria of uncoupling protein-1, a protein that uncouples substrate oxidation from oxidative phosphorylation and leads to the production of heat instead of ATP. BAT thermogenesis depends on proper mitochondrial biogenesis during the differentiation of brown adipocytes. Despite the data that support a role for Endonuclease G (EndoG) in the process of mitochondrial biogenesis, its function in BAT has not been explored. Here, using an EndoG knockout mouse model, we demonstrate that EndoG is not essential for the expression of mitochondrial genes involved in substrate oxidation or for the induction of thermogenic genes in BAT in response to cold exposure. We also show that a lack of EndoG is associated with an increased expression of thermogenic genes (ie, uncoupling protein-1, peroxisome proliferator-activated receptor-γ coactivator-1α) in white adipose tissue (WAT) that correlates with the appearance of brown adipocyte-like cells interspersed among white adipocytes. Interestingly, the increased browning of WAT elicited by the lack of EndoG was associated with a better glucose tolerance and reduced fat mass. Our results suggest that the induction of browning in WAT by means of inhibiting EndoG activity appears as a potential therapeutic strategy to prevent obesity and ameliorate glucose intolerance.
Collapse
Affiliation(s)
- Rosario Pardo
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Natividad Blasco
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Maria Vilà
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Daniel Beiroa
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Rubén Nogueiras
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Xavier Cañas
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Rafael Simó
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Daniel Sanchis
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| | - Josep A Villena
- Laboratory of Metabolism and Obesity (R.P., M.V., J.A.V.) and Group of Diabetes and Metabolism (R.S.), Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; Cell Signaling and Apoptosis Group (N.B., D.S.), Biomedical Research Institute of Lleida, University of Lleida, 25003 Lleida, Spain; Department of Physiology (D.B., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, Universidad de Santiago de Compostela, and Centro de Investigación Biomédica en Red on Physiopathology of Obesity and Nutrition (D.B., R.N.), 15705 Santiago de Compostela, Spain; Laboratory Animal Applied Research Platform (X.C.), Scientific Park of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red on Diabetes and Associated Metabolic Diseases (J.A.V. R.S.), 08003 Barcelona, Spain
| |
Collapse
|
61
|
Martins L, Seoane-Collazo P, Contreras C, González-García I, Martínez-Sánchez N, González F, Zalvide J, Gallego R, Diéguez C, Nogueiras R, Tena-Sempere M, López M. A Functional Link between AMPK and Orexin Mediates the Effect of BMP8B on Energy Balance. Cell Rep 2016; 16:2231-2242. [PMID: 27524625 PMCID: PMC4999418 DOI: 10.1016/j.celrep.2016.07.045] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 06/16/2016] [Accepted: 07/15/2016] [Indexed: 11/30/2022] Open
Abstract
AMP-activated protein kinase (AMPK) in the ventromedial nucleus of the hypothalamus (VMH) and orexin (OX) in the lateral hypothalamic area (LHA) modulate brown adipose tissue (BAT) thermogenesis. However, whether these two molecular mechanisms act jointly or independently is unclear. Here, we show that the thermogenic effect of bone morphogenetic protein 8B (BMP8B) is mediated by the inhibition of AMPK in the VMH and the subsequent increase in OX signaling via the OX receptor 1 (OX1R). Accordingly, the thermogenic effect of BMP8B is totally absent in ox-null mice. BMP8B also induces browning of white adipose tissue (WAT), its thermogenic effect is sexually dimorphic (only observed in females), and its impact on OX expression and thermogenesis is abolished by the knockdown of glutamate vesicular transporter 2 (VGLUT2), implicating glutamatergic signaling. Overall, our data uncover a central network controlling energy homeostasis that may be of considerable relevance for obesity and metabolic disorders. Central BMP8B modulates BAT thermogenesis and browning of WAT AMPK in the VMH mediates central BMP8B actions OX in the LHA mediates central BMP8B actions The AMPK(VMH)-OX(LHA) axis is a functional neuronal pathway regulating energy balance
Collapse
Affiliation(s)
- Luís Martins
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Patricia Seoane-Collazo
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Cristina Contreras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Ismael González-García
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Noelia Martínez-Sánchez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Francisco González
- Department of Surgery, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela 15706, Spain
| | - Juan Zalvide
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
| | - Rosalía Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Manuel Tena-Sempere
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain; Department of Cell Biology, Physiology and Immunology, University of Córdoba, 14004 Córdoba, Spain; Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Reina Sofía, 14004 Córdoba, Spain; FiDiPro Program, Department of Physiology, University of Turku, Kiinamyllynkatu10, 20520 Turku, Finland
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
| |
Collapse
|
62
|
Abstract
AMP-activated protein kinase (AMPK) has a major role in the modulation of energy balance. AMPK is activated in conditions of low energy, increasing energy production and reducing energy consumption. The AMPK pathway is a canonical route regulating energy homeostasis by integrating peripheral signals, such as hormones and metabolites, with neuronal networks. Current evidence has implicated AMPK in the hypothalamus and hindbrain with feeding, brown adipose tissue thermogenesis and browning of white adipose tissue, through modulation of the sympathetic nervous system, as well as glucose homeostasis. Interestingly, several potential antiobesity and/or antidiabetic agents, some of which are currently in clinical use such as metformin and liraglutide, exert some of their actions by acting on AMPK. Furthermore, the orexigenic and weight-gain effects of commonly used antipsychotic drugs are also mediated by hypothalamic AMPK. Overall, this evidence suggests that hypothalamic AMPK signalling is an interesting target for drug development, but is this approach feasible? In this Review we discuss the current understanding of hypothalamic AMPK and its role in the central regulation of energy balance and metabolism.
Collapse
Affiliation(s)
- Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Manuel Tena-Sempere
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
- Department of Cell Biology, Physiology and Immunology, University of Córdoba; Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Reina Sofía, 14004 Córdoba, Spain
- FiDiPro Program, Department of Physiology, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| |
Collapse
|
63
|
Al-Massadi O, Porteiro B, Kuhlow D, Köhler M, Gonzalez-Rellan MJ, Garcia-Lavandeira M, Díaz-Rodríguez E, Quiñones M, Senra A, Alvarez CV, López M, Diéguez C, Schulz TJ, Nogueiras R. Pharmacological and Genetic Manipulation of p53 in Brown Fat at Adult But Not Embryonic Stages Regulates Thermogenesis and Body Weight in Male Mice. Endocrinology 2016; 157:2735-49. [PMID: 27183316 DOI: 10.1210/en.2016-1209] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
p53 is a well-known tumor suppressor that plays multiple biological roles, including the capacity to modulate metabolism at different levels. However, its metabolic role in brown adipose tissue (BAT) remains largely unknown. Herein we sought to investigate the physiological role of endogenous p53 in BAT and its implication on BAT thermogenic activity and energy balance. To this end, we generated and characterized global p53-null mice and mice lacking p53 specifically in BAT. Additionally we performed gain-and-loss-of-function experiments in the BAT of adult mice using virogenetic and pharmacological approaches. BAT was collected and analyzed by immunohistochemistry, thermography, real-time PCR, and Western blot. p53-deficient mice were resistant to diet-induced obesity due to increased energy expenditure and BAT activity. However, the deletion of p53 in BAT using a Myf5-Cre driven p53 knockout did not show any changes in body weight or the expression of thermogenic markers. The acute inhibition of p53 in the BAT of adult mice slightly increased body weight and inhibited BAT thermogenesis, whereas its overexpression in the BAT of diet-induced obese mice reduced body weight and increased thermogenesis. On the other hand, pharmacological activation of p53 improves body weight gain due to increased BAT thermogenesis by sympathetic nervous system in obese adult wild-type mice but not in p53(-/-) animals. These results reveal that p53 regulates BAT metabolism by coordinating body weight and thermogenesis, but these metabolic actions are tissue specific and also dependent on the developmental stage.
Collapse
Affiliation(s)
- Omar Al-Massadi
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Begoña Porteiro
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Doreen Kuhlow
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Markus Köhler
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - María J Gonzalez-Rellan
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Montserrat Garcia-Lavandeira
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Esther Díaz-Rodríguez
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Mar Quiñones
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Ana Senra
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Clara V Alvarez
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Miguel López
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Carlos Diéguez
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Tim J Schulz
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| | - Rubén Nogueiras
- Department of Physiology (O.A.-M., B.P., M.J.G.-R., M.G.-L., E.D.R., M.Q., A.S., C.V.A., M.L., C.D., R.N.), Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (O.A.-M., B.P., M.J.G.-R., M.Q., M.L., C.D., R.N.), Santiago de Compostela 15706, Spain; Department of Adipocyte Development and Nutrition (D.K., M.K., T.J.S.), German Institute of Human Nutrition Potsdam-Rehbrücke, 14558 Nuthetal, Germany; and German Center for Diabetes Research (T.J.S.), München-Neuherberg 85764, Germany
| |
Collapse
|
64
|
Tudurí E, López M, Diéguez C, Nadal A, Nogueiras R. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets. Trends Endocrinol Metab 2016; 27:304-318. [PMID: 27062006 DOI: 10.1016/j.tem.2016.03.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 03/04/2016] [Accepted: 03/04/2016] [Indexed: 02/07/2023]
Abstract
Glucagon-like peptide 1 (GLP-1) exerts many actions that improve glycemic control. GLP-1 stimulates glucose-stimulated insulin secretion and protects β cells, while its extrapancreatic effects include cardioprotection, reduction of hepatic glucose production, and regulation of satiety. Although an appealing antidiabetic drug candidate, the rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) means that its therapeutic use is unfeasible, and this prompted the development of two main GLP-1 therapies: long-acting GLP-1 analogs and DPP-4 inhibitors. In this review, we focus on the pancreatic effects exerted by current GLP-1 derivatives used to treat diabetes. Based on the results from in vitro and in vivo studies in humans and animal models, we describe the specific actions of GLP-1 analogs on the synthesis, processing, and secretion of insulin, islet morphology, and β cell proliferation and apoptosis.
Collapse
Affiliation(s)
- Eva Tudurí
- Instituto de Investigaciones Sanitarias (IDIS), CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
| | - Miguel López
- Instituto de Investigaciones Sanitarias (IDIS), CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain; Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Carlos Diéguez
- Instituto de Investigaciones Sanitarias (IDIS), CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain; Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Angel Nadal
- Instituto de Bioingeniería and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universidad Miguel Hernández, Elche, Spain
| | - Rubén Nogueiras
- Instituto de Investigaciones Sanitarias (IDIS), CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain; Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela 15782, Spain.
| |
Collapse
|
65
|
González-Terán B, Matesanz N, Nikolic I, Verdugo MA, Sreeramkumar V, Hernández-Cosido L, Mora A, Crainiciuc G, Sáiz ML, Bernardo E, Leiva-Vega L, Rodríguez E, Bondía V, Torres JL, Perez-Sieira S, Ortega L, Cuenda A, Sanchez-Madrid F, Nogueiras R, Hidalgo A, Marcos M, Sabio G. p38γ and p38δ reprogram liver metabolism by modulating neutrophil infiltration. EMBO J 2016; 35:536-52. [PMID: 26843485 DOI: 10.15252/embj.201591857] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Accepted: 12/22/2015] [Indexed: 12/29/2022] Open
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major health problem and the main cause of liver disease in Western countries. Although NAFLD is strongly associated with obesity and insulin resistance, its pathogenesis remains poorly understood. The disease begins with an excessive accumulation of triglycerides in the liver, which stimulates an inflammatory response. Alternative p38 mitogen-activated kinases (p38γ and p38δ) have been shown to contribute to inflammation in different diseases. Here we demonstrate that p38δ is elevated in livers of obese patients with NAFLD and that mice lacking p38γ/δ in myeloid cells are resistant to diet-induced fatty liver, hepatic triglyceride accumulation and glucose intolerance. This protective effect is due to defective migration of p38γ/δ-deficient neutrophils to the damaged liver. We further show that neutrophil infiltration in wild-type mice contributes to steatosis development by means of inflammation and liver metabolic changes. Therefore, p38γ and p38δ in myeloid cells provide a potential target for NAFLD therapy.
Collapse
Affiliation(s)
| | - Nuria Matesanz
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Ivana Nikolic
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - María Angeles Verdugo
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | - Vinatha Sreeramkumar
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Lourdes Hernández-Cosido
- Bariatric Surgery Unit, Department of General Surgery, University Hospital of Salamanca, Salamanca, Spain Department of Surgery, University of Salamanca, Salamanca, Spain
| | - Alfonso Mora
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Georgiana Crainiciuc
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - María Laura Sáiz
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Edgar Bernardo
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Luis Leiva-Vega
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Elena Rodríguez
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Victor Bondía
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Jorge L Torres
- Department of Internal Medicine, University Hospital of Salamanca-IBSAL, Salamanca, Spain Department of Medicine, University of Salamanca, Salamanca, Spain
| | - Sonia Perez-Sieira
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Luis Ortega
- Bariatric Surgery Unit, Department of General Surgery, University Hospital of Salamanca, Salamanca, Spain Department of Surgery, University of Salamanca, Salamanca, Spain
| | - Ana Cuenda
- Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Madrid, Spain
| | | | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Andrés Hidalgo
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Miguel Marcos
- Department of Internal Medicine, University Hospital of Salamanca-IBSAL, Salamanca, Spain Department of Medicine, University of Salamanca, Salamanca, Spain
| | - Guadalupe Sabio
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| |
Collapse
|
66
|
Seoane-Collazo P, Fernø J, Gonzalez F, Diéguez C, Leis R, Nogueiras R, López M. Hypothalamic-autonomic control of energy homeostasis. Endocrine 2015; 50:276-91. [PMID: 26089260 DOI: 10.1007/s12020-015-0658-y] [Citation(s) in RCA: 113] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 06/06/2015] [Indexed: 10/23/2022]
Abstract
Regulation of energy homeostasis is tightly controlled by the central nervous system (CNS). Several key areas such as the hypothalamus and brainstem receive and integrate signals conveying energy status from the periphery, such as leptin, thyroid hormones, and insulin, ultimately leading to modulation of food intake, energy expenditure (EE), and peripheral metabolism. The autonomic nervous system (ANS) plays a key role in the response to such signals, innervating peripheral metabolic tissues, including brown and white adipose tissue (BAT and WAT), liver, pancreas, and skeletal muscle. The ANS consists of two parts, the sympathetic and parasympathetic nervous systems (SNS and PSNS). The SNS regulates BAT thermogenesis and EE, controlled by central areas such as the preoptic area (POA) and the ventromedial, dorsomedial, and arcuate hypothalamic nuclei (VMH, DMH, and ARC). The SNS also regulates lipid metabolism in WAT, controlled by the lateral hypothalamic area (LHA), VMH, and ARC. Control of hepatic glucose production and pancreatic insulin secretion also involves the LHA, VMH, and ARC as well as the dorsal vagal complex (DVC), via splanchnic sympathetic and the vagal parasympathetic nerves. Muscle glucose uptake is also controlled by the SNS via hypothalamic nuclei such as the VMH. There is recent evidence of novel pathways connecting the CNS and ANS. These include the hypothalamic AMP-activated protein kinase-SNS-BAT axis which has been demonstrated to be a key modulator of thermogenesis. In this review, we summarize current knowledge of the role of the ANS in the modulation of energy balance.
Collapse
Affiliation(s)
- Patricia Seoane-Collazo
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Santiago de Compostela, Spain.
| | - Johan Fernø
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain
- Department of Clinical Science, K. G. Jebsen Center for Diabetes Research, University of Bergen, 5021, Bergen, Norway
| | - Francisco Gonzalez
- Department of Surgery, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain
| | - Carlos Diéguez
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Santiago de Compostela, Spain
| | - Rosaura Leis
- Unit of Investigation in Nutrition, Growth and Human Development of Galicia, Pediatric Department (USC), Complexo Hospitalario Universitario de Santiago (IDIS/SERGAS), Santiago de Compostela, Spain
| | - Rubén Nogueiras
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Santiago de Compostela, Spain
| | - Miguel López
- NeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782, Santiago de Compostela, Spain.
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Santiago de Compostela, Spain.
| |
Collapse
|
67
|
Tudurí E, Beiroa D, Porteiro B, López M, Diéguez C, Nogueiras R. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice. Diabetes Obes Metab 2015; 17:789-99. [PMID: 25962313 DOI: 10.1111/dom.12488] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 04/24/2015] [Accepted: 05/03/2015] [Indexed: 01/15/2023]
Abstract
AIM To investigate the role of brain glucagon-like peptide-1 (GLP-1) in pancreatic β-cell function. METHODS To determine the role of brain GLP-1 receptor (GLP-1R) on β-cell function, we administered intracerebroventricular (i.c.v.) infusions of GLP-1 or the specific GLP-1 antagonist exendin-9 (Ex-9), in both an acute and a chronic setting. RESULTS We observed that acute i.c.v. GLP-1 infusion potentiates glucose-stimulated insulin secretion (GSIS) and improves glucose tolerance, whereas central GLP-1R blockade with Ex-9 impaired glucose excursion after a glucose load. Sustained activation of central nervous system GLP-1R, however, did not produce any effect on either GSIS or glucose tolerance. Similarly, ex vivo GSIS performed in islets from mice chronically infused with i.c.v. GLP-1 resulted in no differences compared with controls. In addition, in mice fed a high-fat diet we observed that acute i.c.v. GLP-1 infusion improved glucose tolerance without changes in GSIS, while chronic GLP-1R activation had no effect on glucose homeostasis. CONCLUSIONS Our results indicate that, under non-clamped conditions, brain GLP-1 plays a functional neuroendocrine role in the acute regulation of glucose homeostasis in both lean and obese rodents.
Collapse
Affiliation(s)
- E Tudurí
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - D Beiroa
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - B Porteiro
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - M López
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - C Diéguez
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - R Nogueiras
- Instituto de Investigaciones Sanitarias, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
68
|
Garcés MF, Vallejo SA, Sanchez E, Palomino-Palomino MA, Leal LG, Ángel-Muller E, Díaz-Cruz LA, Ruíz-Parra AI, González-Clavijo AM, Castaño JP, Abba M, Lacunza E, Diéguez C, Nogueiras R, Caminos JE. Longitudinal analysis of maternal serum Follistatin concentration in normal pregnancy and preeclampsia. Clin Endocrinol (Oxf) 2015; 83:229-35. [PMID: 25565002 DOI: 10.1111/cen.12715] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Revised: 11/30/2014] [Accepted: 12/31/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Follistatin (FST) is a regulator of the biological activity of activin A (Act A), binding and blocking it, which could contribute to the modulation of its pro-inflammatory activity during pregnancy. We sought to investigate, in this nested case-control study, FST serum levels during normal pregnancy and correlate it with the FST profile in preeclamptic pregnant women, normal pregnant women followed 3 months postpartum and eumenorrheic nonpregnant women throughout the menstrual cycle. SUBJECTS AND METHODS Follistatin serum levels determined by ELISA, biochemical and anthropometric variables were measured in normal pregnant (n = 28) and preeclamptic (n = 20) women during three periods of gestation. In addition, FST serum levels were measured in a subset of normal pregnant women (n = 13) followed 3 months postpartum and in eumenorrheic nonpregnant women (n = 20) during the follicular and luteal phases of the menstrual cycle. RESULTS Follistatin serum levels in the eumenorrheic nonpregnant and postpartum group were significantly lower when compared to levels throughout gestation (P < 0·01). Serum FST levels increased in each period of pregnancy analysed, being significantly higher towards the end of gestation (P < 0·01). FST levels were lower in late pregnancy in preeclamptic women compared to normal pregnant women (P < 0·05). Finally, FST levels were higher in the luteal phase when compared with the follicular phase of the menstrual cycle (P < 0·05). CONCLUSIONS These analyses would permit the consideration that changes in FST levels during pregnancy contribute to the control of the Act A system.
Collapse
Affiliation(s)
- María F Garcés
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Sergio A Vallejo
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Elizabeth Sanchez
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | | | - Luis G Leal
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Edith Ángel-Muller
- Department of Obstetrics and Gynecology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Luz A Díaz-Cruz
- Department of Obstetrics and Gynecology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Ariel Iván Ruíz-Parra
- Department of Obstetrics and Gynecology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | | | - Justo P Castaño
- Department of Cell Biology, Physiology and Immunology, University of Córdoba, Reina Sofía University Hospital, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Spain
| | - Martin Abba
- CINIBA, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina
| | - Ezequiel Lacunza
- CINIBA, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina
| | - Carlos Diéguez
- Department of Physiology (CIMUS), School of Medicine-Instituto de Investigaciones Sanitarias (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Spain
| | - Rubén Nogueiras
- Department of Physiology (CIMUS), School of Medicine-Instituto de Investigaciones Sanitarias (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Spain
| | - Jorge E Caminos
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| |
Collapse
|
69
|
Abstract
Ghrelin is a pleiotropic and ubiquitous gastric hormone implicated in body physiology. Ghrelin exhibits potent orexigenic actions and increases body weight and adiposity. Ghrelin is also involved in other metabolic functions among which we can highlight the GH releasing activity and the regulation of glucose homeostasis. Ghrelin needs the enzyme GOAT to be acylated, a step essential for binding to the GHSR1a receptor to exert its functions. Genetic animal models emerge as important tools to delineate the physiological relevance of ghrelin on energy balance. Despite the numerous reports using different genetically engineered mouse models targeting the ghrelin system, its endogenous relevance in metabolism seems to be less important than its pharmaceutical options.
Collapse
Affiliation(s)
- Omar Al Massadi
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), University of Santiago de Compostela, Avda. Barcelona s/n, 15782 Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Santiago de Compostela (A Coruña) 15706, Spain.
| | - Miguel López
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), University of Santiago de Compostela, Avda. Barcelona s/n, 15782 Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Santiago de Compostela (A Coruña) 15706, Spain
| | - Johan Fernø
- Department of Clinical Science, K. G. Jebsen Center for Diabetes Research, University of Bergen, Bergen N-5020, Norway
| | - Carlos Diéguez
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), University of Santiago de Compostela, Avda. Barcelona s/n, 15782 Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Santiago de Compostela (A Coruña) 15706, Spain
| | - Rubén Nogueiras
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), University of Santiago de Compostela, Avda. Barcelona s/n, 15782 Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Santiago de Compostela (A Coruña) 15706, Spain.
| |
Collapse
|
70
|
Garcés MF, Sanchez E, Cardona LF, Simanca EL, González I, Leal LG, Mora JA, Bedoya A, Alzate JP, Sánchez ÁY, Eslava-Schmalbach JH, Franco-Vega R, Parra MO, Ruíz-Parra AI, Diéguez C, Nogueiras R, Caminos JE. Maternal Serum Meteorin Levels and the Risk of Preeclampsia. PLoS One 2015; 10:e0131013. [PMID: 26121675 PMCID: PMC4487999 DOI: 10.1371/journal.pone.0131013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Accepted: 05/26/2015] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Meteorin (METRN) is a recently described neutrophic factor with angiogenic properties. This is a nested case-control study in a longitudinal cohort study that describes the serum profile of METRN during different periods of gestation in healthy and preeclamptic pregnant women. Moreover, we explore the possible application of METRN as a biomarker. METHODS AND FINDINGS Serum METRN was measured by ELISA in a longitudinal prospective cohort study in 37 healthy pregnant women, 16 mild preeclamptic women, and 20 healthy non-pregnant women during the menstrual cycle with the aim of assessing serum METRN levels and its correlations with other metabolic parameters. Immunostaining for METRN protein was performed in placenta. A multivariate logistic regression model was proposed and a classifier model was formulated for predicting preeclampsia in early and middle pregnancy. The performance in classification was evaluated using measures such as sensitivity, specificity, and the receiver operating characteristic (ROC) curve. In healthy pregnant women, serum METRN levels were significantly elevated in early pregnancy compared to middle and late pregnancy. METRN levels are significantly lower only in early pregnancy in preeclamptic women when compared to healthy pregnant women. Decision trees that did not include METRN levels in the first trimester had a reduced sensitivity of 56% in the detection of preeclamptic women, compared to a sensitivity of 69% when METRN was included. CONCLUSIONS The joint measurements of circulating METRN levels in the first trimester and systolic blood pressure and weight in the second trimester significantly increase the probabilities of predicting preeclampsia.
Collapse
Affiliation(s)
- María F Garcés
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Elizabeth Sanchez
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Luisa F Cardona
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Elkin L Simanca
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Iván González
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Luis G Leal
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - José A Mora
- Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Andrés Bedoya
- Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Juan P Alzate
- Institute of Clinical Investigations, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Ángel Y Sánchez
- Department of Pathology School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Javier H Eslava-Schmalbach
- Institute of Clinical Investigations, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Roberto Franco-Vega
- Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Mario O Parra
- Department of Obstetrics and Gynecology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Ariel I Ruíz-Parra
- Department of Obstetrics and Gynecology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | - Carlos Diéguez
- Department of Physiology (CIMUS), School of Medicine-Instituto de Investigaciones Sanitarias (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain; Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - Rubén Nogueiras
- Department of Physiology (CIMUS), School of Medicine-Instituto de Investigaciones Sanitarias (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain; Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - Jorge E Caminos
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| |
Collapse
|
71
|
Abstract
The link between smoking and insulin resistance, despite weight loss, is well established; however, the underlying mechanisms remain elusive. A recent article published in Nature Medicine by Wu et al. (2015) reports that nicotine, the main bioactive component of tobacco smoke, activates AMPKα2 in adipocytes, leading to impaired insulin sensitivity.
Collapse
Affiliation(s)
- Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
| |
Collapse
|
72
|
López M, Diéguez C, Nogueiras R. Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat. Adipocyte 2015; 4:141-5. [PMID: 26167417 DOI: 10.4161/21623945.2014.983752] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Revised: 10/28/2014] [Accepted: 10/30/2014] [Indexed: 11/19/2022] Open
Abstract
Brown adipose tissue (BAT) is a specialized organ responsible for thermogenesis, a process required for maintaining body temperature. Since the discovery that BAT and brite/beige cells are functional in adult humans, many studies have been focusing on the physiology and functionality of this organ. The brain is controlling the maintenance of body temperature through a complex neuronal network. One of the candidates to modulate thermogenesis at central level is glucagon-like peptide-1 (GLP-1), with GLP-1 receptors widely expressed throughout the brain. Our group has recently reported that stimulation of brain GLP-1 receptors in the ventromedial nucleus of the hypothalamus is essential for the activation not only of BAT thermogenesis, but also browning of white fat. Notably, both actions are mediated by specific inhibition of the energy sensor AMP-activated protein kinase (AMPK). In this commentary, we summarize the latest results on this topic, as well as the potential clinical relevance of the brain GLP-1 system to treat obesity.
Collapse
|
73
|
Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrère B, LeRoux CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LHT, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH. Ghrelin. Mol Metab 2015; 4:437-60. [PMID: 26042199 PMCID: PMC4443295 DOI: 10.1016/j.molmet.2015.03.005] [Citation(s) in RCA: 680] [Impact Index Per Article: 75.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 03/11/2015] [Accepted: 03/11/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence supports more complicated and nuanced roles for the hormone, which go beyond the regulation of systemic energy metabolism. SCOPE OF REVIEW In this review, we discuss the diverse biological functions of ghrelin, the regulation of its secretion, and address questions that still remain 15 years after its discovery. MAJOR CONCLUSIONS In recent years, ghrelin has been found to have a plethora of central and peripheral actions in distinct areas including learning and memory, gut motility and gastric acid secretion, sleep/wake rhythm, reward seeking behavior, taste sensation and glucose metabolism.
Collapse
Affiliation(s)
- T D Müller
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, München, Germany
| | - R Nogueiras
- Department of Physiology, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, University of Santiago de Compostela (CIMUS)-Instituto de Investigación Sanitaria (IDIS)-CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - M L Andermann
- Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Z B Andrews
- Department of Physiology, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia
| | - S D Anker
- Applied Cachexia Research, Department of Cardiology, Charité Universitätsmedizin Berlin, Germany
| | - J Argente
- Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Madrid, Spain ; Department of Pediatrics, Universidad Autónoma de Madrid and CIBER Fisiopatología de la obesidad y nutrición, Instituto de Salud Carlos III, Madrid, Spain
| | - R L Batterham
- Centre for Obesity Research, University College London, London, United Kingdom
| | - S C Benoit
- Metabolic Disease Institute, Division of Endocrinology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - C Y Bowers
- Tulane University Health Sciences Center, Endocrinology and Metabolism Section, Peptide Research Section, New Orleans, LA, USA
| | - F Broglio
- Division of Endocrinology, Diabetes and Metabolism, Dept. of Medical Sciences, University of Torino, Torino, Italy
| | - F F Casanueva
- Department of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS), CIBER de Fisiopatologia Obesidad y Nutricion (CB06/03), Instituto Salud Carlos III, Santiago de Compostela, Spain
| | - D D'Alessio
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - I Depoortere
- Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium
| | - A Geliebter
- New York Obesity Nutrition Research Center, Department of Medicine, St Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - E Ghigo
- Department of Pharmacology & Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - P A Cole
- Monash Obesity & Diabetes Institute, Monash University, Clayton, Victoria, Australia
| | - M Cowley
- Department of Physiology, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia ; Monash Obesity & Diabetes Institute, Monash University, Clayton, Victoria, Australia
| | - D E Cummings
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - A Dagher
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
| | - S Diano
- Dept of Neurobiology, Yale University School of Medicine, New Haven, CT, USA
| | - S L Dickson
- Department of Physiology/Endocrinology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
| | - C Diéguez
- Department of Physiology, School of Medicine, Instituto de Investigacion Sanitaria (IDIS), University of Santiago de Compostela, Spain
| | - R Granata
- Division of Endocrinology, Diabetes and Metabolism, Dept. of Medical Sciences, University of Torino, Torino, Italy
| | - H J Grill
- Department of Psychology, Institute of Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA, USA
| | - K Grove
- Department of Diabetes, Obesity and Metabolism, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
| | - K M Habegger
- Comprehensive Diabetes Center, University of Alabama School of Medicine, Birmingham, AL, USA
| | - K Heppner
- Division of Diabetes, Obesity, and Metabolism, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA
| | - M L Heiman
- NuMe Health, 1441 Canal Street, New Orleans, LA 70112, USA
| | - L Holsen
- Departments of Psychiatry and Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - B Holst
- Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen N, Denmark
| | - A Inui
- Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - J O Jansson
- Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
| | - H Kirchner
- Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany
| | - M Korbonits
- Centre for Endocrinology, William Harvey Research Institute, Barts and the London, Queen Mary University of London, London, UK
| | - B Laferrère
- New York Obesity Research Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - C W LeRoux
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Ireland
| | - M Lopez
- Department of Physiology, Centro de Investigación en Medicina Molecular y Enfermedades Crónicas, University of Santiago de Compostela (CIMUS)-Instituto de Investigación Sanitaria (IDIS)-CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - S Morin
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, München, Germany
| | - M Nakazato
- Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan
| | - R Nass
- Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, VA, USA
| | - D Perez-Tilve
- Department of Internal Medicine, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - P T Pfluger
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, München, Germany
| | - T W Schwartz
- Department of Neuroscience and Pharmacology, Laboratory for Molecular Pharmacology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
| | - R J Seeley
- Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA
| | - M Sleeman
- Department of Physiology, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia
| | - Y Sun
- Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - L Sussel
- Department of Genetics and Development, Columbia University, New York, NY, USA
| | - J Tong
- Duke Molecular Physiology Institute, Duke University, Durham, NC, USA
| | - M O Thorner
- Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, VA, USA
| | - A J van der Lely
- Department of Medicine, Erasmus University MC, Rotterdam, The Netherlands
| | | | - J M Zigman
- Departments of Internal Medicine and Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - M Kojima
- Molecular Genetics, Institute of Life Science, Kurume University, Kurume, Japan
| | - K Kangawa
- National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - R G Smith
- The Scripps Research Institute, Florida Department of Metabolism & Aging, Jupiter, FL, USA
| | - T Horvath
- Program in Integrative Cell Signaling and Neurobiology of Metabolism, Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT, USA
| | - M H Tschöp
- Institute for Diabetes and Obesity, Helmholtz Zentrum München, München, Germany ; Division of Metabolic Diseases, Department of Medicine, Technical University Munich, Munich, Germany
| |
Collapse
|
74
|
Gurriarán-Rodríguez U, Santos-Zas I, González-Sánchez J, Beiroa D, Moresi V, Mosteiro CS, Lin W, Viñuela JE, Señarís J, García-Caballero T, Casanueva FF, Nogueiras R, Gallego R, Renaud JM, Adamo S, Pazos Y, Camiña JP. Action of obestatin in skeletal muscle repair: stem cell expansion, muscle growth, and microenvironment remodeling. Mol Ther 2015; 23:1003-1021. [PMID: 25762009 DOI: 10.1038/mt.2015.40] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Accepted: 01/29/2015] [Indexed: 12/14/2022] Open
Abstract
The development of therapeutic strategies for skeletal muscle diseases, such as physical injuries and myopathies, depends on the knowledge of regulatory signals that control the myogenic process. The obestatin/GPR39 system operates as an autocrine signal in the regulation of skeletal myogenesis. Using a mouse model of skeletal muscle regeneration after injury and several cellular strategies, we explored the potential use of obestatin as a therapeutic agent for the treatment of trauma-induced muscle injuries. Our results evidenced that the overexpression of the preproghrelin, and thus obestatin, and GPR39 in skeletal muscle increased regeneration after muscle injury. More importantly, the intramuscular injection of obestatin significantly enhanced muscle regeneration by simulating satellite stem cell expansion as well as myofiber hypertrophy through a kinase hierarchy. Added to the myogenic action, the obestatin administration resulted in an increased expression of vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR2) and the consequent microvascularization, with no effect on collagen deposition in skeletal muscle. Furthermore, the potential inhibition of myostatin during obestatin treatment might contribute to its myogenic action improving muscle growth and regeneration. Overall, our data demonstrate successful improvement of muscle regeneration, indicating obestatin is a potential therapeutic agent for skeletal muscle injury and would benefit other myopathies related to muscle regeneration.
Collapse
Affiliation(s)
- Uxía Gurriarán-Rodríguez
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain; Current address: Sprott Centre for Stem Cell Research, Ottawa Health Research Institute, Ottawa, Canada
| | - Icía Santos-Zas
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain
| | - Jessica González-Sánchez
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain
| | - Daniel Beiroa
- CIBER Fisiopatología de la Obesidad y Nutrición, Spain; Departamento de Fisiología, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Viviana Moresi
- Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy; Interuniversity Institute of Myology, Rome, Italy
| | - Carlos S Mosteiro
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain
| | - Wei Lin
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada
| | - Juan E Viñuela
- Unidad de Inmunología, CHUS, Santiago de Compostela, Spain
| | - José Señarís
- Servicio de Cirugía Ortopédica y Traumatología, CHUS, SERGAS, Santiago de Compostela, Spain
| | | | - Felipe F Casanueva
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain; Departamento de Medicina, USC, Santiago de Compostela, Spain
| | - Rubén Nogueiras
- CIBER Fisiopatología de la Obesidad y Nutrición, Spain; Departamento de Fisiología, Universidad de Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Rosalía Gallego
- Departamento de Ciencias Morfológicas, USC, Santiago de Compostela, Spain
| | - Jean-Marc Renaud
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada
| | - Sergio Adamo
- Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy; Interuniversity Institute of Myology, Rome, Italy
| | - Yolanda Pazos
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain
| | - Jesús P Camiña
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Spain.
| |
Collapse
|
75
|
Folgueira C, Sanchez-Rebordelo E, Barja-Fernandez S, Leis R, Tovar S, Casanueva FF, Dieguez C, Nogueiras R, Seoane LM. Uroguanylin levels in intestine and plasma are regulated by nutritional status in a leptin-dependent manner. Eur J Nutr 2015; 55:529-536. [DOI: 10.1007/s00394-015-0869-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2014] [Accepted: 02/25/2015] [Indexed: 01/09/2023]
|
76
|
Abstract
Brown adipose tissue (BAT) is a specialized organ responsible for thermogenesis, a process required for maintaining body temperature. BAT is regulated by the sympathetic nervous system (SNS), which activates lipolysis and mitochondrial uncoupling in brown adipocytes. For many years, BAT was considered to be important only in small mammals and newborn humans, but recent data have shown that BAT is also functional in adult humans. On the basis of this evidence, extensive research has been focused on BAT function, where new molecules, such as irisin and bone morphogenetic proteins, particularly BMP7 and BMP8B, as well as novel central factors and new regulatory mechanisms, such as orexins and the canonical ventomedial nucleus of the hypothalamus (VMH) AMP- activated protein kinase (AMPK)-SNS-BAT axis, have been discovered and emerged as potential drug targets to combat obesity. In this review we provide an overview of the complex central regulation of BAT and how different neuronal cell populations co-ordinately work to maintain energy homeostasis.
Collapse
Affiliation(s)
- Cristina Contreras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria , Santiago de Compostela, 15782 , Spain
| | | | | | | | | | | | | |
Collapse
|
77
|
Lear PV, González-Touceda D, Porteiro Couto B, Viaño P, Guymer V, Remzova E, Tunn R, Chalasani A, García-Caballero T, Hargreaves IP, Tynan PW, Christian HC, Nogueiras R, Parrington J, Diéguez C. Absence of intracellular ion channels TPC1 and TPC2 leads to mature-onset obesity in male mice, due to impaired lipid availability for thermogenesis in brown adipose tissue. Endocrinology 2015; 156:975-86. [PMID: 25545384 PMCID: PMC4330317 DOI: 10.1210/en.2014-1766] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 12/23/2014] [Indexed: 12/11/2022]
Abstract
Intracellular calcium-permeable channels have been implicated in thermogenic function of murine brown and brite/beige adipocytes, respectively transient receptor potential melastin-8 and transient receptor potential vanilloid-4. Because the endo-lysosomal two-pore channels (TPCs) have also been ascribed with metabolic functionality, we studied the effect of simultaneously knocking out TPC1 and TPC2 on body composition and energy balance in male mice fed a chow diet. Compared with wild-type mice, TPC1 and TPC2 double knockout (Tpcn1/2(-/-)) animals had a higher respiratory quotient and became obese between 6 and 9 months of age. Although food intake was unaltered, interscapular brown adipose tissue (BAT) maximal temperature and lean-mass adjusted oxygen consumption were lower in Tpcn1/2(-/-) than in wild type mice. Phosphorylated hormone-sensitive lipase expression, lipid density and expression of β-adrenergic receptors were also lower in Tpcn1/2(-/-) BAT, whereas mitochondrial respiratory chain function and uncoupling protein-1 expression remained intact. We conclude that Tpcn1/2(-/-) mice show mature-onset obesity due to reduced lipid availability and use, and a defect in β-adrenergic receptor signaling, leading to impaired thermogenic activity, in BAT.
Collapse
Affiliation(s)
- Pamela V. Lear
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | | | | | - Patricia Viaño
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Vanessa Guymer
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Elena Remzova
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Ruth Tunn
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Annapurna Chalasani
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Tomás García-Caballero
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Iain P. Hargreaves
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Patricia W. Tynan
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Helen C. Christian
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | - Rubén Nogueiras
- Department of Physiology (P.V.L., D.G.-T., B.P.C., R.N., C.D.), Centre for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela and Institute of Health Sciences, and Department of Morphological Sciences (P.V., T.G.-C.), School of Medicine and University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology (P.V.L., R.T., P.W.T., J.P.), Oxford University, Oxford OX1 3QT, United Kingdom; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (D.G.-T., B.P.C., R.N., C.D.), 15706, Santiago de Compostela, Spain; Department of Physiology, Anatomy, and Genetics (V.G., H.C.C.), Oxford University, Oxford OX1 3QX, United Kingdom; and Neurometabolic Unit (E.R., A.C., I.P.H.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, Queen Square, London WC1N 3BG, United Kingdom
| | | | | |
Collapse
|
78
|
Martínez de Morentin PB, Lage R, González-García I, Ruíz-Pino F, Martins L, Fernández-Mallo D, Gallego R, Fernø J, Señarís R, Saha AK, Tovar S, Diéguez C, Nogueiras R, Tena-Sempere M, López M. Pregnancy induces resistance to the anorectic effect of hypothalamic malonyl-CoA and the thermogenic effect of hypothalamic AMPK inhibition in female rats. Endocrinology 2015; 156:947-60. [PMID: 25535827 PMCID: PMC4330316 DOI: 10.1210/en.2014-1611] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Accepted: 12/19/2014] [Indexed: 12/20/2022]
Abstract
During gestation, hyperphagia is necessary to cope with the metabolic demands of embryonic development. There were three main aims of this study: Firstly, to investigate the effect of pregnancy on hypothalamic fatty acid metabolism, a key pathway for the regulation of energy balance; secondly, to study whether pregnancy induces resistance to the anorectic effect of fatty acid synthase (FAS) inhibition and accumulation of malonyl-coenzyme A (CoA) in the hypothalamus; and, thirdly, to study whether changes in hypothalamic AMPK signaling are associated with brown adipose tissue (BAT) thermogenesis during pregnancy. Our data suggest that in pregnant rats, the hypothalamic fatty acid pathway shows an overall state that should lead to anorexia and elevated BAT thermogenesis: decreased activities of AMP-activated protein kinase (AMPK), FAS, and carnitine palmitoyltransferase 1, coupled with increased acetyl-CoA carboxylase function with subsequent elevation of malonyl-CoA levels. This profile seems dependent of estradiol levels but not prolactin or progesterone. Despite the apparent anorexic and thermogenic signaling in the hypothalamus, pregnant rats remain hyperphagic and display reduced temperature and BAT function. Actually, pregnant rats develop resistance to the anorectic effects of central FAS inhibition, which is associated with a reduction of proopiomelanocortin (POMC) expression and its transcription factors phospho-signal transducer and activator of transcription 3, and phospho-forkhead box O1. This evidence demonstrates that pregnancy induces a state of resistance to the anorectic and thermogenic actions of hypothalamic cellular signals of energy surplus, which, in parallel to the already known refractoriness to leptin effects, likely contributes to gestational hyperphagia and adiposity.
Collapse
Affiliation(s)
- Pablo B Martínez de Morentin
- Department of Physiology, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (P.B.M.d.M., R.L., I.G.-G., L.M., D.F.M., R.S., S.T., C.D., R.N., M.L.), University of Santiago de Compostela (USC)-Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela 15782, Spain; Centro de Investigación Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBERobn) (P.B.M.d.M., R.L., I.G.-G., F.R.-P., L.M., D.F.M., S.T., C.D., R.N., M.T.-S., M.L.), Santiago de Compostela 15706, Spain; Department of Cell Biology, Physiology and Immunology (F.R.-P., M.T.-S.), University of Córdoba, Córdoba 14004, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofía (F.R.-P., M.T.-S.), Córdoba 14004, Spain; Department of Morphological Sciences (R.G.), School of Medicine, University of Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Clinical Science (J.F.), K. G. Jebsen Center for Diabetes Research, University of Bergen, Bergen, N-5021, Norway; and Diabetes Research Unit, EBRC-827 (A.K.S.), Boston Medical Center, Boston, Massachusetts 02118
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
79
|
Contreras C, González-García I, Martínez-Sánchez N, Seoane-Collazo P, Jacas J, Morgan DA, Serra D, Gallego R, Gonzalez F, Casals N, Nogueiras R, Rahmouni K, Diéguez C, López M. Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balance. Cell Rep 2014; 9:366-377. [PMID: 25284795 PMCID: PMC5157160 DOI: 10.1016/j.celrep.2014.08.057] [Citation(s) in RCA: 177] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 08/07/2014] [Accepted: 08/23/2014] [Indexed: 12/30/2022] Open
Abstract
Hypothalamic endoplasmic reticulum (ER) stress is a key mechanism leading to obesity. Here, we demonstrate that ceramides induce lipotoxicity and hypothalamic ER stress, leading to sympathetic inhibition, reduced brown adipose tissue (BAT) thermogenesis, and weight gain. Genetic overexpression of the chaperone GRP78/BiP (glucose-regulated protein 78 kDa/binding immunoglobulin protein) in the ventromedial nucleus of the hypothalamus (VMH) abolishes ceramide action by reducing hypothalamic ER stress and increasing BAT thermogenesis, which leads to weight loss and improved glucose homeostasis. The pathophysiological relevance of this mechanism is demonstrated in obese Zucker rats, which show increased hypothalamic ceramide levels and ER stress. Overexpression of GRP78 in the VMH of these animals reduced body weight by increasing BAT thermogenesis as well as decreasing leptin and insulin resistance and hepatic steatosis. Overall, these data identify a triangulated signaling network involving central ceramides, hypothalamic lipotoxicity/ER stress, and BAT thermogenesis as a pathophysiological mechanism of obesity.
Collapse
Affiliation(s)
- Cristina Contreras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Ismael González-García
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Noelia Martínez-Sánchez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Patricia Seoane-Collazo
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Jordi Jacas
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain; Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallés, 08195 Barcelona, Spain
| | - Donald A Morgan
- Department of Pharmacology, University of Iowa, Iowa City, IA 52242, USA
| | - Dolors Serra
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain; Department of Biochemistry and Molecular Biology, School of Pharmacy, Institut de Biomedicina (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain
| | - Rosalía Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Francisco Gonzalez
- Department of Surgery, CIMUS, University of Santiago de Compostela-Instituto de Invesstiagacion Sanitaria, 15782 Santiago de Compostela, Spain; Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Núria Casals
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain; Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallés, 08195 Barcelona, Spain
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Kamal Rahmouni
- Department of Pharmacology, University of Iowa, Iowa City, IA 52242, USA; Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 15782 Santiago de Compostela, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706 Santiago de Compostela, Spain.
| |
Collapse
|
80
|
Abstract
Over the past few decades, obesity and its related metabolic disorders have increased at an epidemic rate in the developed and developing world. New signals and factors involved in the modulation of energy balance and metabolism are continuously being discovered, providing potential novel drug targets for the treatment of metabolic disease. A parallel strategy is to better understand how hormonal signals, with an already established role in energy metabolism, work, and how manipulation of the pathways involved may lead to amelioration of metabolic dysfunction. The thyroid hormones belong to the latter category, with dysregulation of the thyroid axis leading to marked alterations in energy balance. The potential of thyroid hormones in the treatment of obesity has been known for decades, but their therapeutic use has been hampered because of side-effects. Data gleaned over the past few years, however, have uncovered new features at the mechanisms of action involved in thyroid hormones. Sophisticated neurobiological approaches have allowed the identification of specific energy sensors, such as AMP-activated protein kinase and mechanistic target of rapamycin, acting in specific groups of hypothalamic neurons, mediating many of the effects of thyroid hormones on food intake, energy expenditure, glucose, lipid metabolism, and cardiovascular function. More extensive knowledge about these molecular mechanisms will be of great relevance for the treatment of obesity and metabolic syndrome.
Collapse
Affiliation(s)
- Noelia Martínez-Sánchez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| | - Clara V Alvarez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| | - Johan Fernø
- Department of Clinical Science, K. G. Jebsen Center for Diabetes Research, University of Bergen, Bergen, Norway.
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| | - Carlos Diéguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| |
Collapse
|
81
|
Martínez de Morentin PB, González-García I, Martins L, Lage R, Fernández-Mallo D, Martínez-Sánchez N, Ruíz-Pino F, Liu J, Morgan DA, Pinilla L, Gallego R, Saha AK, Kalsbeek A, Fliers E, Bisschop PH, Diéguez C, Nogueiras R, Rahmouni K, Tena-Sempere M, López M. Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK. Cell Metab 2014; 20:41-53. [PMID: 24856932 PMCID: PMC4082097 DOI: 10.1016/j.cmet.2014.03.031] [Citation(s) in RCA: 304] [Impact Index Per Article: 30.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 02/16/2014] [Accepted: 03/26/2014] [Indexed: 12/18/2022]
Abstract
Estrogens play a major role in the modulation of energy balance through central and peripheral actions. Here, we demonstrate that central action of estradiol (E2) inhibits AMP-activated protein kinase (AMPK) through estrogen receptor alpha (ERα) selectively in the ventromedial nucleus of the hypothalamus (VMH), leading to activation of thermogenesis in brown adipose tissue (BAT) through the sympathetic nervous system (SNS) in a feeding-independent manner. Genetic activation of AMPK in the VMH prevented E2-induced increase in BAT-mediated thermogenesis and weight loss. Notably, fluctuations in E2 levels during estrous cycle also modulate this integrated physiological network. Together, these findings demonstrate that E2 regulation of the VMH AMPK-SNS-BAT axis is an important determinant of energy balance and suggest that dysregulation in this axis may account for the common changes in energy homeostasis and obesity linked to dysfunction of the female gonadal axis.
Collapse
Affiliation(s)
- Pablo B Martínez de Morentin
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Ismael González-García
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Luís Martins
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Ricardo Lage
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Diana Fernández-Mallo
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Noelia Martínez-Sánchez
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Francisco Ruíz-Pino
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, 14004 Spain; Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Universitario Reina Sofia (HURS), Córdoba, 14004, Spain
| | - Ji Liu
- Department of Endocrinology and Metabolism, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands; Department of Hypothalamic Integration Mechanisms, Netherlands Institute of Neuroscience (NIN), an Institute of the Royal Netherlands Academy of Arts and Science, Amsterdam, 1105 BA, The Netherlands; Key Laboratory of Brain Function and Diseases, School of Life Sciences, University of Science and Technology of China, Chinese Academy of Sciences, Hefei, Anhui, 230026, P. R. China
| | - Donald A Morgan
- Department of Pharmacology, University of Iowa, Iowa City, IA 52242, USA
| | - Leonor Pinilla
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, 14004 Spain; Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Universitario Reina Sofia (HURS), Córdoba, 14004, Spain
| | - Rosalía Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | - Asish K Saha
- Diabetes Research Unit, EBRC-827, Boston Medical Center, Boston, MA 02118, USA
| | - Andries Kalsbeek
- Department of Endocrinology and Metabolism, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands; Department of Hypothalamic Integration Mechanisms, Netherlands Institute of Neuroscience (NIN), an Institute of the Royal Netherlands Academy of Arts and Science, Amsterdam, 1105 BA, The Netherlands
| | - Eric Fliers
- Department of Endocrinology and Metabolism, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Peter H Bisschop
- Department of Endocrinology and Metabolism, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands
| | - Carlos Diéguez
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Rubén Nogueiras
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain
| | - Kamal Rahmouni
- Department of Pharmacology, University of Iowa, Iowa City, IA 52242, USA; Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
| | - Manuel Tena-Sempere
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, 14004 Spain; Instituto Maimónides de Investigación Biomédica (IMIBIC)/Hospital Universitario Reina Sofia (HURS), Córdoba, 14004, Spain
| | - Miguel López
- Department of Physiology, Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, 15706, Spain.
| |
Collapse
|
82
|
Garcés MF, Sanchez E, Torres-Sierra AL, Ruíz-Parra AI, Angel-Müller E, Alzate JP, Sánchez ÁY, Gomez MA, Romero XC, Castañeda ZE, Sanchez-Rebordelo E, Diéguez C, Nogueiras R, Caminos JE. Brain-derived neurotrophic factor is expressed in rat and human placenta and its serum levels are similarly regulated throughout pregnancy in both species. Clin Endocrinol (Oxf) 2014; 81:141-51. [PMID: 24372023 DOI: 10.1111/cen.12391] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 10/28/2013] [Accepted: 12/15/2013] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Pregnancy is characterized by several metabolic changes that promote fat gain and later onset of insulin resistance. As Brain-derived neurotrophic factor (BDNF) decreases hyperglycaemia and hyperphagia, we aimed to investigate the potential role of placental and circulating BDNF levels in these pregnancy-related metabolic changes in rats and humans. DESIGN AND METHODS We identified the mRNA and protein expression of placental BDNF and its receptor TrkB using real-time PCR, Western blot and immunohistochemical approaches in both rat and humans. Serum BDNF was measured by ELISA. We also did a longitudinal prospective cohort study in 42 pregnant women to assess BDNF levels and correlations with other metabolic parameters. RESULTS We found that BDNF and TrkB are expressed in both rat and human placenta. In rat, both placental mRNA and serum levels are increased throughout pregnancy, whereas their protein levels are significantly decreased at the end of gestation. Serum BDNF levels in pregnant women are significantly lower in the first trimester when compared to the second and third trimester (P < 0·0148, P < 0·0012, respectively). Serum BDNF levels were negatively correlated with gestational age at birth and fasting glucose levels. CONCLUSION Our findings suggest that both BDNF and its receptor TrkB are expressed in rodent and human placenta being regulated during pregnancy. Taken together, these findings support a role of BDNF in the regulation of several metabolic functions during pregnancy.
Collapse
Affiliation(s)
- María F Garcés
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
83
|
Garcés MF, Peralta JJ, Ruiz-Linares CE, Lozano AR, Poveda NE, Torres-Sierra AL, Eslava-Schmalbach JH, Alzate JP, Sánchez AY, Sanchez E, Angel-Müller E, Ruíz-Parra AI, Diéguez C, Nogueiras R, Caminos JE. Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab 2014; 99:2113-9. [PMID: 24628554 DOI: 10.1210/jc.2013-4127] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Irisin is a recently discovered adipomyokine that regulates the differentiation and phenotype of adipose tissue. OBJECTIVE In this study, we investigated the levels of irisin over the three trimesters of gestation in healthy and preeclamptic women and during the follicular and luteal phase of the menstrual cycle in a cohort of healthy eumenoherric women. METHODS Serum irisin was measured by an ELISA in a longitudinal prospective cohort study in 40 healthy pregnant women, 10 mild preeclamptic women, and 20 healthy eumenoherric women during the menstrual cycle to assess irisin levels and correlations with other metabolic parameters. We identified the protein expression of fibronectin type III domain-containing protein 5, the irisin precursor, in human placenta using immunohistochemical approaches in humans. RESULTS Serum irisin levels are higher in the luteal than in the follicular phase in eumenorrheic women. Fibronectin type III domain-containing protein 5, the irisin precursor, is expressed in human placenta, and its serum levels are higher during the entire pregnancy when compared with nonpregnant women. Serum irisin correlates positively with the homeostasis model assessment of estimated insulin resistance in the first trimester of normal pregnancy. Serum irisin levels do not change throughout gestation in preeclamptic women; however, there were lower irisin levels during the third trimester when compared with the normal pregnant group. CONCLUSION Our results suggest that irisin may be involved in reproductive function and in the pregnancy-associated metabolic changes, and this condition may be an irisin-resistant state during gestation.
Collapse
Affiliation(s)
- María F Garcés
- Departments of Physiology (M.F.G., J.J.P., C.E.R.-L., A.R.L., N.E.P., A.L.T.-S., E.S., J.E.C.), Pathology (A.Y.S.), and Obstetrics and Gynecology (E.A.-M., A.I.R.-P.) and Institute of Clinical Investigations (J.H.E.-S., P.A., A.I.R.-P.), School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia; Department of Physiology, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (C.D., R.N., J.E.C.), School of Medicine-Instituto de Investigaciones Sanitarias, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; and Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (C.D., R.N.), 28029 Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
84
|
Garcés MF, Poveda NE, Sanchez E, Sánchez ÁY, Bravo SB, Vázquez MJ, Diéguez C, Nogueiras R, Caminos JE. Regulation of NucB2/Nesfatin-1 throughout rat pregnancy. Physiol Behav 2014; 133:216-22. [DOI: 10.1016/j.physbeh.2014.05.042] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2014] [Revised: 04/16/2014] [Accepted: 05/28/2014] [Indexed: 01/26/2023]
|
85
|
Seoane-Collazo P, Martínez de Morentin PB, Fernø J, Diéguez C, Nogueiras R, López M. Nicotine improves obesity and hepatic steatosis and ER stress in diet-induced obese male rats. Endocrinology 2014; 155:1679-89. [PMID: 24517227 DOI: 10.1210/en.2013-1839] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Nicotine, the main addictive component of tobacco, promotes body weight reduction in humans and rodents. Recent evidence has suggested that nicotine acts in the central nervous system to modulate energy balance. Specifically, nicotine modulates hypothalamic AMP-activated protein kinase to decrease feeding and to increase brown adipose tissue thermogenesis through the sympathetic nervous system, leading to weight loss. Of note, most of this evidence has been obtained in animal models fed with normal diet or low-fat diet (LFD). However, its effectiveness in obese models remains elusive. Because obesity causes resistance towards many factors involved in energy homeostasis, the aim of this study has been to compare the effect of nicotine in a diet-induced obese (DIO) model, namely rats fed a high-fat diet, with rats fed a LFD. Our data show that chronic peripheral nicotine treatment reduced body weight by decreasing food intake and increasing brown adipose tissue thermogenesis in both LFD and DIO rats. This overall negative energy balance was associated to decreased activation of hypothalamic AMP-activated protein kinase in both models. Furthermore, nicotine improved serum lipid profile, decreased insulin serum levels, as well as reduced steatosis, inflammation, and endoplasmic reticulum stress in the liver of DIO rats but not in LFD rats. Overall, this evidence suggests that nicotine diminishes body weight and improves metabolic disorders linked to DIO and might offer a clear-cut strategy to develop new therapeutic approaches against obesity and its metabolic complications.
Collapse
Affiliation(s)
- Patricia Seoane-Collazo
- Department of Physiology (P.S.-C., P.B.M.d.M., C.D., R.N., M.L.), NeuObesity Group, Centro singular de investigación en medicina molecular y enfermedades crónicas (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; Centro de investigación biomédica en red Fisiopatología de la Obesidad y Nutrición (P.S.-C., P.B.M.d.M., C.D., R.N., M.L.), Santiago de Compostela 15706, Spain; and Department of Clinical Science (J.F.), University of Bergen, N-5020 Bergen, Norway
| | | | | | | | | | | |
Collapse
|
86
|
Pérez-Sieira S, López M, Nogueiras R, Tovar S. Regulation of NR4A by nutritional status, gender, postnatal development and hormonal deficiency. Sci Rep 2014; 4:4264. [PMID: 24584059 PMCID: PMC3939456 DOI: 10.1038/srep04264] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Accepted: 02/14/2014] [Indexed: 01/11/2023] Open
Abstract
The NR4A is a subfamily of the orphan nuclear receptors (NR) superfamily constituted by three well characterized members: Nur77 (NR4A1), Nurr1 (NR4A2) and Nor 1 (NR4A3). They are implicated in numerous biological processes as DNA repair, arteriosclerosis, cell apoptosis, carcinogenesis and metabolism. Several studies have demonstrated the role of this subfamily on glucose metabolism, insulin sensitivity and energy balance. These studies have focused mainly in liver and skeletal muscle. However, its potential role in white adipose tissue (WAT), one of the most important tissues involved in the regulation of energy homeostasis, is not well-studied. The aim of this work was to elucidate the regulation of NR4A in WAT under different physiological and pathophysiological settings involved in energy balance such as fasting, postnatal development, gender, hormonal deficiency and pregnancy. We compared NR4A mRNA expression of Nur77, Nurr1 and Nor 1 and found a clear regulation by nutritional status, since the expression of the 3 isoforms is increased after fasting in a leptin-independent manner and sex steroid hormones also modulate NR4A expression in males and females. Our findings indicate that NR4A are regulated by different physiological and pathophysiological settings known to be associated with marked alterations in glucose metabolism and energy status.
Collapse
Affiliation(s)
- S Pérez-Sieira
- 1] Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain [2] CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - M López
- 1] Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain [2] CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - R Nogueiras
- 1] Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain [2] CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - S Tovar
- 1] Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain [2] CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| |
Collapse
|
87
|
Martínez de Morentin P, Martinez-Sanchez N, Roa J, Ferno J, Nogueiras R, Tena-Sempere M, Dieguez C, Lopez M. Hypothalamic mTOR: The Rookie Energy Sensor. Curr Mol Med 2014; 14:3-21. [DOI: 10.2174/1566524013666131118103706] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2013] [Revised: 04/08/2013] [Accepted: 04/14/2013] [Indexed: 11/22/2022]
|
88
|
Abstract
The sirtuins are a family of highly conserved nicotine adenine dinucleotide (NAD+)-dependent deacetylases that act as cellular sensors to detect energy availability and regulate metabolic processes. Sirtuin 1 (SIRT1) is one of the family members that is activated in response to caloric restriction, acting on multiple targets in a wide range of tissues. Recent studies have shown that SIRT1 controls glucose and lipid metabolism in both liver and muscle, promotes fat mobilization, stimulates remodeling of white to brown fat, controls insulin secretion in the pancreas, and senses nutrient availability in the hypothalamus. SIRT1 is located in several areas of the brain and its central metabolic actions have attracted much attention in the last decade. In this short review, we summarize the main actions and molecular pathways triggered by SIRT1 that control feeding behavior, energy expenditure, glucose metabolism, and insulin sensitivity, with an emphasis on the emerging role of SIRT1 in the brain.
Collapse
Affiliation(s)
- O Al Massadi
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), San Francisco s/n, Santiago de Compostela (A Coruña), Spain
| | - M Quiñones
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), San Francisco s/n, Santiago de Compostela (A Coruña), Spain
| | - P Lear
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), San Francisco s/n, Santiago de Compostela (A Coruña), Spain
| | - C Dieguez
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), San Francisco s/n, Santiago de Compostela (A Coruña), Spain
| | - R Nogueiras
- Department of Physiology, School of Medicine-CIMUS, Instituto de Investigacion Sanitaria (IDIS), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), San Francisco s/n, Santiago de Compostela (A Coruña), Spain
| |
Collapse
|
89
|
Suárez J, Rivera P, Arrabal S, Crespillo A, Serrano A, Baixeras E, Pavón FJ, Cifuentes M, Nogueiras R, Ballesteros J, Dieguez C, Rodríguez de Fonseca F. Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 2013; 7:129-41. [PMID: 24159189 PMCID: PMC3882055 DOI: 10.1242/dmm.013110] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
β-adrenergic receptor activation promotes brown adipose tissue (BAT) β-oxidation and thermogenesis by burning fatty acids during uncoupling respiration. Oleoylethanolamide (OEA) can inhibit feeding and stimulate lipolysis by activating peroxisome proliferator-activating receptor-α (PPARα) in white adipose tissue (WAT). Here we explore whether PPARα activation potentiates the effect of β3-adrenergic stimulation on energy balance mediated by the respective agonists OEA and CL316243. The effect of this pharmacological association on feeding, thermogenesis, β-oxidation, and lipid and cholesterol metabolism in epididymal (e)WAT was monitored. CL316243 (1 mg/kg) and OEA (5 mg/kg) co-administration over 6 days enhanced the reduction of both food intake and body weight gain, increased the energy expenditure and reduced the respiratory quotient (VCO2/VO2). This negative energy balance agreed with decreased fat mass and increased BAT weight and temperature, as well as with lowered plasma levels of triglycerides, cholesterol, nonessential fatty acids (NEFAs), and the adipokines leptin and TNF-α. Regarding eWAT, CL316243 and OEA treatment elevated levels of the thermogenic factors PPARα and UCP1, reduced p38-MAPK phosphorylation, and promoted brown-like features in the white adipocytes: the mitochondrial (Cox4i1, Cox4i2) and BAT (Fgf21, Prdm16) genes were overexpressed in eWAT. The enhancement of the fatty-acid β-oxidation factors Cpt1b and Acox1 in eWAT was accompanied by an upregulation of de novo lipogenesis and reduced expression of the unsaturated-fatty-acid-synthesis enzyme gene, Scd1. We propose that the combination of β-adrenergic and PPARα receptor agonists promotes therapeutic adipocyte remodelling in eWAT, and therefore has a potential clinical utility in the treatment of obesity.
Collapse
Affiliation(s)
- Juan Suárez
- Laboratorio de Medicina Regenerativa, Hospital Carlos Haya-IBIMA (Pabellón de Gobierno), Avenida, Carlos Haya 82, 29010 Málaga, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
90
|
Álvarez-Crespo M, Martínez-Sánchez N, Ruíz-Pino F, Garcia-Lavandeira M, Alvarez CV, Tena-Sempere M, Nogueiras R, Diéguez C, López M. The orexigenic effect of orexin-A revisited: dependence of an intact growth hormone axis. Endocrinology 2013; 154:3589-98. [PMID: 23861376 DOI: 10.1210/en.2013-1251] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Fifteen years ago orexins were identified as central regulators of energy homeostasis. Since then, that concept has evolved considerably and orexins are currently considered, besides orexigenic neuropeptides, key modulators of sleep-wake cycle and neuroendocrine function. Little is known, however, about the effect of the neuroendocrine milieu on orexins' effects on energy balance. We therefore investigated whether hypothalamic-pituitary axes have a role in the central orexigenic action of orexin A (OX-A) by centrally injecting hypophysectomized, adrenalectomized, gonadectomized (male and female), hypothyroid, and GH-deficient dwarf rats with OX-A. Our data showed that the orexigenic effect of OX-A is fully maintained in adrenalectomized and gonadectomized (females and males) rats, slightly reduced in hypothyroid rats, and totally abolished in hypophysectomized and dwarf rats when compared with their respective vehicle-treated controls. Of note, loss of the OX-A effect on feeding was associated with a blunted OX-A-induced increase in the expression of either neuropeptide Y or its putative regulator, the transcription factor cAMP response-element binding protein, as well as its phosphorylated form, in the arcuate nucleus of the hypothalamus of hypophysectomized and dwarf rats. Overall, this evidence suggests that the orexigenic action of OX-A depends on an intact GH axis and that this neuroendocrine feedback loop may be of interest in the understanding of orexins action on energy balance and GH deficiency.
Collapse
Affiliation(s)
- Mayte Álvarez-Crespo
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain and CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
91
|
Porteiro B, Díaz-Ruíz A, Martínez G, Senra A, Vidal A, Serrano M, Gualillo O, López M, Malagón MM, Diéguez C, Nogueiras R. Ghrelin requires p53 to stimulate lipid storage in fat and liver. Endocrinology 2013; 154:3671-9. [PMID: 23832961 DOI: 10.1210/en.2013-1176] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Ghrelin, a stomach-derived peptide, stimulates feeding behavior and adiposity. For its orexigenic action, ghrelin triggers a central SIRT1/p53/AMPK pathway. The tumor suppressor p53 also plays an important role in white adipose tissue (WAT), where it is up-regulated in the adipocytes of obese mice. It is not known, however, whether p53 has any role in mediating the peripheral action of ghrelin. In the present study, chronic peripheral ghrelin treatment resulted in increased body weight and fat-mass gain in wild-type mice. Correspondingly, mRNA levels of several adipogenic and fat-storage-promoting enzymes were up-regulated in WAT, whereas hepatic triglyceride content and lipogenic enzymes were also increased in wild-type mice following ghrelin treatment. In contrast, mice lacking p53 failed to respond to ghrelin treatment, with their body weight, fat mass, and adipocyte and hepatic metabolism remaining unchanged. Thus, our results show that p53 is necessary for the actions of ghrelin on WAT and liver, leading to changes in expression levels of lipogenic and adipogenic genes, and modifying body weight.
Collapse
Affiliation(s)
- Begoña Porteiro
- Department of Physiology, Centre of Research in Molecular Medicine and Chronic Diseases of the University of Santiago de Compostela (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Avda Barcelona s/n, 15782, Santiago de Compostela (A Coruña), Spain, and CIBER "Fisiopatología de la Obesidad y Nutrición," Instituto de Salud Carlos III, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Menacho-Márquez M, Nogueiras R, Fabbiano S, Sauzeau V, Al-Massadi O, Diéguez C, Bustelo XR. Chronic sympathoexcitation through loss of Vav3, a Rac1 activator, results in divergent effects on metabolic syndrome and obesity depending on diet. Cell Metab 2013; 18:199-211. [PMID: 23931752 DOI: 10.1016/j.cmet.2013.07.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Revised: 05/27/2013] [Accepted: 07/03/2013] [Indexed: 02/07/2023]
Abstract
The role of the sympathetic nervous system, stress, and hypertension in metabolic syndrome and obesity remains unclear. To clarify this issue, we utilized genetically engineered mice showing chronic sympathoexcitation and hypertension due to lack of Vav3, a Rac1 activator. Here, we report that these animals develop metabolic syndrome under chow diet. However, they show protection from metabolic syndrome and obesity under fatty diets. These effects are elicited by α1-adrenergic- and diet-dependent metabolic changes in liver and the α1/β3 adrenergic-mediated stimulation of brown adipocyte thermogenesis. These responses seem to be engaged by the local action of noradrenaline in target tissues rather than by long-range effects of adrenaline. By contrast, they are not triggered by low parasympathetic drive or the hypertensive state present in Vav3-deficient mice. These results indicate that the sympathetic system plays divergent roles in the etiology of metabolic diseases depending on food regimen, sympathoexcitation source, and disease stage.
Collapse
Affiliation(s)
- Mauricio Menacho-Márquez
- Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Científicas-University of Salamanca, Spain
| | | | | | | | | | | | | |
Collapse
|
93
|
|
94
|
López M, Alvarez CV, Nogueiras R, Diéguez C. Energy balance regulation by thyroid hormones at central level. Trends Mol Med 2013; 19:418-27. [PMID: 23707189 DOI: 10.1016/j.molmed.2013.04.004] [Citation(s) in RCA: 129] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2013] [Revised: 04/23/2013] [Accepted: 04/25/2013] [Indexed: 12/21/2022]
Abstract
Classically, medical textbooks taught that most effects of thyroid hormones (THs) on energy homeostasis are directly exerted in peripheral tissues. However, current evidence is changing (and challenging) our perspective about the role of THs from a 'peripheral' to a 'central' vision, implying that they affect food intake, energy expenditure, and metabolism by acting, to a large extent, at the central level. Interestingly, effects of THs are interrelated with global energy sensors in the central nervous system (CNS), such as uncoupling protein 2 (UCP2), AMP-activated protein kinase (AMPK; the 'AMPK-BAT axis'), and mechanistic target of rapamycin (mTOR). Here, we review what is currently known about THs and their regulation of energy balance and metabolism in both peripheral and central tissues.
Collapse
Affiliation(s)
- Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain.
| | | | | | | |
Collapse
|
95
|
Garces MF, Sanchez E, Ruíz-Parra AI, Rubio-Romero JA, Angel-Müller E, Suarez MA, Bohórquez LF, Bravo SB, Nogueiras R, Diéguez C, Caminos JE. Serum chemerin levels during normal human pregnancy. Peptides 2013; 42:138-43. [PMID: 23313148 DOI: 10.1016/j.peptides.2013.01.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Revised: 12/31/2012] [Accepted: 01/02/2013] [Indexed: 01/11/2023]
Abstract
During gestation there are important changes in maternal metabolism and an increase in insulin resistance, coinciding with an increase in adiposity. Chemerin is an adipocytokine which is expressed and secreted in various tissues, including placenta, and may play an important role in metabolic regulation during pregnancy. The aim of this study was to determine serum levels of chemerin during gestation and compare them to other indicators of insulin resistance. A cross-sectional study was carried out analyzing serum chemerin levels of 20 pregnant women during three gestational periods, early, middle, and late (between the 10th and 14th, the 23rd and 26th, and the 34th and 37th week) and 20 non-pregnant women were used as a control group. An analysis of chemerin levels during the menstrual cycle was performed in an eumenorrheic group (n=16) in the early follicular (cycle day 4±1) and the midluteal phase (cycle day 22±1), demonstrating that serum chemerin levels did not fluctuate significantly. Serum levels of chemerin were significantly elevated during late gestation when compared to early (P<0.001) and middle (P=0.001) gestation and a negative correlation between serum chemerin and adiponectin levels (r=-0.1643) became more significant when the non-pregnant group was included in the calculations (r=-0.2471). There was no significant association of triglycerides, total cholesterol, LDL, HDL, insulin, and HOMA levels with chemerin. Although chemerin rose significantly and is negatively associated with adiponectin levels, it is not correlated with other markers of insulin sensitivity, suggesting that more study is needed to determine whether chemerin is useful in predicting insulin resistance during gestation.
Collapse
Affiliation(s)
- Maria F Garces
- Department of Physiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
96
|
Gurriarán-Rodríguez U, Santos-Zas I, Al-Massadi O, Mosteiro CS, Beiroa D, Nogueiras R, Crujeiras AB, Seoane LM, Señarís J, García-Caballero T, Gallego R, Casanueva FF, Pazos Y, Camiña JP. The obestatin/GPR39 system is up-regulated by muscle injury and functions as an autocrine regenerative system. J Biol Chem 2012; 287:38379-89. [PMID: 22992743 DOI: 10.1074/jbc.m112.374926] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
The maintenance and repair of skeletal muscle are attributable to an elaborate interaction between extrinsic and intrinsic regulatory signals that regulate the myogenic process. In the present work, we showed that obestatin, a 23-amino acid peptide encoded by the ghrelin gene, and the GPR39 receptor are expressed in rat skeletal muscle and are up-regulated upon experimental injury. To define their roles in muscle regeneration, L6E9 cells were used to perform in vitro assays. For the in vivo assays, skeletal muscle tissue was obtained from male rats and maintained under continuous subcutaneous infusion of obestatin. In differentiating L6E9 cells, preproghrelin expression and correspondingly obestatin increased during myogenesis being sustained throughout terminal differentiation. Autocrine action was demonstrated by neutralization of the endogenous obestatin secreted by differentiating L6E9 cells using a specific anti-obestatin antibody. Knockdown experiments by preproghrelin siRNA confirmed the contribution of obestatin to the myogenic program. Furthermore, GPR39 siRNA reduced obestatin action and myogenic differentiation. Exogenous obestatin stimulation was also shown to regulate myoblast migration and proliferation. Furthermore, the addition of obestatin to the differentiation medium increased myogenic differentiation of L6E9 cells. The relevance of the actions of obestatin was confirmed in vivo by the up-regulation of Pax-7, MyoD, Myf5, Myf6, myogenin, and myosin heavy chain (MHC) in obestatin-infused rats when compared with saline-infused rats. These data elucidate a novel mechanism whereby the obestatin/GPR39 system is coordinately regulated as part of the myogenic program and operates as an autocrine signal regulating skeletal myogenesis.
Collapse
Affiliation(s)
- Uxía Gurriarán-Rodríguez
- Área de Endocrinología Molecular y Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
97
|
Tovar SA, Seoane LM, Caminos JE, Nogueiras R, Casanueva FF, Diéguez C. Regulation of Peptide YY Levels by Age, Hormonal, and Nutritional Status. ACTA ACUST UNITED AC 2012; 12:1944-50. [PMID: 15687395 DOI: 10.1038/oby.2004.244] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE Peptide YY (PYY) 3-36 has recently been recognized as an important gut hormone that influences food intake. Peripheral injections of PYY 3-36 in rats inhibit food intake in experimental animals as well as in lean and obese human subjects. This hormone has been suggested as an attractive therapeutic option for obesity. The aim of this study was to assess the influence of age, sex, thyroid status, growth hormone (GH), pregnancy, and food restriction on PYY levels in rat. RESEARCH METHODS AND PROCEDURES We determined plasma PYY levels in all experimental sets. RESULTS PYY levels were influenced by age, with the highest hormone levels achieved in early postnatal life (day 10) and decreasing thereafter. PYY levels were also dependent on thyroid hormone status being decreased in hyperthyroid rats. Exogenous GH administration led to a clear-cut decrease in PYY levels in both normal and GH-deficient rats. Acute food deprivation or chronic food restriction led to decreased PYY levels in virgin and pregnant rats. In pregnant rats with food available ad libitum, PYY levels were enhanced at late gestation. DISCUSSION Our observations indicate that PYY levels are influenced by age, thyroid hormones, and GH. These data indicate that PYY could be involved in the changes of food intake associated with these conditions. The PYY levels observed in acute and chronic food-restricted rats indicate that, in situations of decreased energy intake, the lower PYY levels could serve to disinhibit central pathways and facilitate food intake.
Collapse
Affiliation(s)
- Sulay A Tovar
- Department of Physiology, Faculty of Medicine, University of Santiago de Compostela, Spain
| | | | | | | | | | | |
Collapse
|
98
|
Garces M, Sanchez E, Acosta B, Angel E, Ruíz A, Rubio-Romero J, Diéguez C, Nogueiras R, Caminos J. Expression and regulation of chemerin during rat pregnancy. Placenta 2012; 33:373-8. [DOI: 10.1016/j.placenta.2012.02.007] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2011] [Revised: 02/04/2012] [Accepted: 02/06/2012] [Indexed: 12/26/2022]
|
99
|
González CR, Martínez de Morentin PB, Martínez-Sánchez N, Gómez-Díaz C, Lage R, Varela L, Diéguez C, Nogueiras R, Castaño JP, López M. Hyperthyroidism differentially regulates neuropeptide S system in the rat brain. Brain Res 2012; 1450:40-8. [PMID: 22425186 DOI: 10.1016/j.brainres.2012.02.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2011] [Revised: 01/23/2012] [Accepted: 02/10/2012] [Indexed: 12/14/2022]
Abstract
Thyroid hormones play an important role in the regulation of energy balance, sleep and emotional behaviors. Neuropeptide S (NPS) is a recently discovered neuropeptide, regulating feeding, sleep and anxiety. Here, we examined the effect of hyperthyroidism on the gene and protein expression of neuropeptide S and its receptor (NPS-R) in the hypothalamus, brainstem and amygdala of rats. Our results showed that the expression of NPS and NPS-R was differentially modulated by hyperthyroidism in the rat brain. NPS and NPS-R mRNA and protein levels were decreased in the hypothalamus of hyperthyroid rats. Conversely NPS-R expression was highly increased in the brainstem and NPS and NPS-R expression were unchanged in the amygdala of these rats. These data suggest that changes in anxiety and food intake patterns observed in hyperthyroidism could be associated with changes in the expression of NPS and NPS-R. Thus, the NPS/NPS-R system may be involved in several hyperthyroidism-associated comorbidities.
Collapse
Affiliation(s)
- Carmen R González
- Department of Physiology, School of Medicine-CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela (A Coruña), Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Martínez de Morentin PB, Whittle AJ, Fernø J, Nogueiras R, Diéguez C, Vidal-Puig A, López M. Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes 2012; 61:807-17. [PMID: 22315316 PMCID: PMC3314364 DOI: 10.2337/db11-1079] [Citation(s) in RCA: 131] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Accepted: 12/08/2011] [Indexed: 02/05/2023]
Abstract
Smokers around the world commonly report increased body weight after smoking cessation as a major factor that interferes with their attempts to quit. Numerous controlled studies in both humans and rodents have reported that nicotine exerts a marked anorectic action. The effects of nicotine on energy homeostasis have been mostly pinpointed in the central nervous system, but the molecular mechanisms controlling its action are still not fully understood. The aim of this study was to investigate the effect of nicotine on hypothalamic AMP-activated protein kinase (AMPK) and its effect on energy balance. Here we demonstrate that nicotine-induced weight loss is associated with inactivation of hypothalamic AMPK, decreased orexigenic signaling in the hypothalamus, increased energy expenditure as a result of increased locomotor activity, increased thermogenesis in brown adipose tissue (BAT), and alterations in fuel substrate utilization. Conversely, nicotine withdrawal or genetic activation of hypothalamic AMPK in the ventromedial nucleus of the hypothalamus reversed nicotine-induced negative energy balance. Overall these data demonstrate that the effects of nicotine on energy balance involve specific modulation of the hypothalamic AMPK-BAT axis. These targets may be relevant for the development of new therapies for human obesity.
Collapse
Affiliation(s)
- Pablo B. Martínez de Morentin
- Department of Physiology, School of Medicine-CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Andrew J. Whittle
- Institute of Metabolic Science, Metabolic Research Laboratories, NIHR Cambridge Biomedical Research Centre Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K
| | - Johan Fernø
- Dr. Einar Martens’ Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - Rubén Nogueiras
- Department of Physiology, School of Medicine-CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Carlos Diéguez
- Department of Physiology, School of Medicine-CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| | - Antonio Vidal-Puig
- Institute of Metabolic Science, Metabolic Research Laboratories, NIHR Cambridge Biomedical Research Centre Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K
| | - Miguel López
- Department of Physiology, School of Medicine-CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain
| |
Collapse
|